Memory-improving activity of Melissa officinalis extract in naïve and scopolamine-treated Rats

Research in Pharmaceutical Sciences

Volumn 9, Issue 2, 2014, Pages 107-114

  Soodi, M ^a   Naghdi, N ^b   Hajimehdipoor, H ^c   Choopani, S ^b   Sahraei, E ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acetylcholinesterase activity; Alzheimer's disease; Melissa officinalis; Memory; Scopolamine; Water maze

Indexed keywords

ACETYLCHOLINESTERASE; ALCOHOL; MELISSA OFFICINALIS EXTRACT; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG ISOLATION; ENZYME ACTIVITY; HIPPOCAMPUS; LEARNING DISORDER; MALE; MAZE TEST; MEASUREMENT; MELISSA OFFICINALIS; MEMORY DISORDER; NONHUMAN; PLANT LEAF; RAT;

EID: 84886384978     PISSN: 17355362     EISSN: 17359414     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Terry AV, Callahan PM, Hall B, Webster SJ. Alzheimer's disease and age-related memory decline (preclinical). Pharmacol Biochem Behav. 2011;99:190-210.
2. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother. 2008;8:1703-1718.
3. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68:209-245.
4. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat. 2003;26:233-242.
5. Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neurosci Biobehav Rev. 2010;34:1307-1350.
6. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database. Syst Rev. 2006;1:CD005593.
7. Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors. Pharmacol Ther. 2012;134:8-25.
8. Anekonda TS, Reddy PH. Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res Rev. 2005;50:361-376.
9. Naghibi F, Mosaddegh M, MohammadiMotamed S, Ghorbani A. Labiatae Family in folk medicine in Iran: from ethnobotany to pharmacology. Iran J Pharm Res. 2005;2:63-79.
10. Dastmalchi K, DamienDorman HJ, Oinonena PP, Darwis Y, Laakso I, Hiltunen R. Chemical composition and in vitro antioxidative activity of a lemon balm (Melissa officinalis L.) extract. LWT. 2008;41:391-400.
11. Wake G, Court J, Pickering A, Lewis R, Wilkins R, Perry E. CNS acetylcholine receptor activity in european medicinal plants traditionally used to improve failing memory. J Ethnopharmacol. 2000;69:105-114.
12. Soulimani R, Fleurentin J, Mortier F, Misslin R, Derrieu G, Pelt JM. Neurotropic action of the hydroalcoholic extract of Melissa officinalis in the mouse. Planta Med. 1991;57:105-109.
13. Sepand M, Soodi M, Soleimani M, Hajimehdipoor H. Protective effects of Melissa officinalis extract against beta-amyloid-induced oxidative stress in PC12 cells. J Med Plants. 2012;11:74-85.
14. Kwon SH, Lee HK, Kim JA, Hong SI, Kim HC, Jo TH et al. Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via antiacetylcholinesterase and anti-oxidative activities in mice. Eur J Pharmacol. 2010;649:210-217.
15. De Quervain DJ, Roozendaal B, McGaugh JL. Stress and glucocorticoids impair retrieval of long-term spatial memory. Nature. 1998;394:787-790.
16. Akbari E, Naghdi N, Motamedi F. Functional inactivation of orexin 1 receptors in CA1 region impairs acquisition, consolidation and retrieval in Morris water maze task. Behav Brain Res. 2006;173:47-52.
17. Spijker S. Dissection of rodent brain regions. In Wan Li KW editor. Neuromethods, Spiringer publisher; 2011. p. 13-26.
18. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88-95.
19. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
20. Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol. 2006;16:710-715.
21. Ennaceur A, Meliani K. Effects of physostigmine and scopolamine on rats'performances in object-recognition and radial-maze tests. Psychopharmacol. 1992;109:321-330.
22. Hodges DB Jr, Lindner MD, Hogan JB, Jones KM, Markus EJ. Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity. Behav Pharmacol. 2009;20:237-251.
23. Fan Y, Hu J, Li J, Yang Z, Xin X, Wang J, et al. Effect of acidic oligosaccharide sugar chain on scopolamineinduced memory impairment in rats and its related mechanisms. Neurosci Lett. 2005;374:222-226.
24. Jeong EJ, Lee KY, Kim SH, Sung SH, Kim YC. Cognitive-enhancing and antioxidant activities of iridoid glycosides from Scrophularia buergeriana in scopolamine-treated mice. Eur J Pharmacol. 2008;588:78-84.
25. Yoshida S, Suzuki N. Antiammnestic and cholinomimetic side effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats. Eur J Pharmacol. 1993;150:117-124.
26. Bejar C, Wang RH, MartaWeinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol. 1999;383:231-240.
27. Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol. 1998;349:137-142.
28. Braida D, Paladini E, Griffini P, Lamperti M, Maggi A, Sala M. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol. 1996;302:13-20.
29. Tian S, Huang F, Li P, Li Z, Zhou S, Deng H, et al. Nicotine enhances contextual fear memory reconsolidation in rats. Neurosci Lett. 2011;487:368-371.
30. Placzek AN, Zhang TA, Dani JA. Nicotinic mechanisms influencing synaptic plasticity in the hippocampus. Acta Pharmacol Sin. 2009;30:752-760.
31. Sharifzadeh M, Tavasoli M, Naghdi N, Ghanbari A, Amini M, Roghani A. Post-training intrahippocampal infusion of nicotine prevents spatial memory retention deficits induced by the cyclo-oxygenase-2-specific inhibitor celecoxib in rats. J Neurochem. 2005;95:1078-1090.
32. Decker MW, Majchrzak MJ. Effects of central nicotinic cholinergic receptor blockade produced by chlorisondamine on learning and memory performance in rats. Behav Neural Biol. 1993;60:163-171.
33. Masuoka T, Kamei C. The role of nicotinic receptors in the amelioration of cholinesterase inhibitors in scopolamine-induced memory deficits. Psychopharmacol. 2009;206:259-265.
34. nd ed. Montvale:2000 Medical Economics Company, Inc: 2000. p. 461-463.
35. Patora J, Klimek B. Flavonoids from lemon balm (Melissa officinalis L., Lamiaceae). Acta Pol Pharm. 2002;59:139-143.
36. Norouzi M, Soleimani T, Pasha Zanousi M. Essential oil component in leaf and flower of Lemon balm (Melissa officinalis L.). Res Pharm Sci. 2012;7:S749.
37. Dastmalchi K, Ollilainen V, Lackman P, Boije af Gennas G, Dorman HJ, Jarvinen PP, et al. Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L. Bioorg Med Chem. 2009;17:867-871.
38. Tsai FS, Peng WH, Wang WH, Wu CR, Hsieh CC, Lin YT, et al. Effects of luteolin on learning acquisition in rats: involvement of the central cholinergic system. Life Sci. 2007;80:1692-1698.
39. Tsai FS, Cheng HY, Hsieh MT, Wu CR, Lin YC, Peng WH. The ameliorating effects of luteolin on betaamyloid-induced impairment of water maze performance and passive avoidance in rats. Am J Chin Med. 2010;38:279-291.
40. Lu J, Zheng YL, Wu DM, Luo L, Sun DX, Shan Q. Ursolic acid ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose. Biochem Pharmacol. 2007;74:1078-1090.